BAM
MDCO

Blueshift Asset Management’s Medicines Co MDCO Stock Holding History

Blueshift Asset Management’s Portfolio MDCO Stock Details MDCO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-21,939
Closed -$420K – 1014
2018
Q4 		$420K Buy
+21,939
New +$510K 0.08% 395

Other funds holding MDCO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

Blueshift Asset Management's MDCO Position: Q1 2019 in Review

Blueshift Asset Management sold out of Medicines Co (MDCO) in Q1 2019, closing a stake of 21,939 shares — an estimated $420K sold.

Blueshift Asset Management first reported a position in MDCO in Q4 2018 and held it in 1 quarter. The position peaked at $420K in Q4 2018. 203 funds tracked by Wall St. Rank hold MDCO as of Q1 2019.

  • Blueshift Asset Management reported no remaining Medicines Co position as of Q1 2019 after selling out during the quarter.
  • Blueshift Asset Management sold 21,939 Medicines Co shares in Q1 2019, an estimated $420K.
  • Blueshift Asset Management first reported a position in Medicines Co in Q4 2018 and held it in 1 quarter.
  • Blueshift Asset Management's Medicines Co position peaked at $420K in Q4 2018.
  • 203 funds tracked by Wall St. Rank held Medicines Co as of Q1 2019.

Based on Blueshift Asset Management's 13F filing for Q1 2019, filed 14 May 2019.